Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has scheduled a conference call for 7th August 2020 at 9:00 AM Eastern Time to announce its 2Q20 financial results.
The financial results for the quarter are released after the U.S. market close on Thursday 6th August 2020
The conference call will also be webcast live under the investor relations section of the website www.ymabs.com
Quarterly Results
Y-mAbs Therapeutics, Inc. communicated loss for the second quarter of $ 1.01 per share, from the revenue of . The quarterly revenues compared with the same quarter last year. Wall street analysts are predicting, loss of $ 0.68 per share The bottom line results missed street analysts by $ 0.33 or 48.53 percent, at the same time, top line results analysts by $ 64.54 million or .
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center.